Journal
INTERNATIONAL IMMUNOPHARMACOLOGY
Volume 101, Issue -, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.intimp.2021.108213
Keywords
Schisandrin B; T(H)1 cell; STAT1; T-bet
Categories
Funding
- Provincial Natural Sci-ence Foundation of Zhejiang [LQ20H160018, LQ21H100002]
- Hangzhou Health Science and Technology plan [OO20191170]
Ask authors/readers for more resources
The study found that Sch B may promote the differentiation of CD4(+) T cells into T(H)1 subset through regulating the STAT1/T-bet signaling pathway, without affecting T(H)2 and Treg cell differentiation.
Schisandrin B (Sch B) is the major active ingredient of the traditional Chinese medicine Schisandra chinensis and has antitumor activity, anti-inflammatory activity. CD4(+) Th subsets orchestrate immune responses to plenty of pathogen infections and participate in the pathogenesis of many immune-related diseases. However, little is known about the relationship between Sch B and T cell differentiation. Here, we showed that Sch B might participate in T cell receptor signaling pathway by using the TCMIO database. Importantly, Sch B promoted T(H)1 cell differentiation. Furthermore, Sch B did not affect T(H)2 cell and Treg differentiation. Mechanismly, Sch B increased the level of IFN-gamma of CD4(+) T cells by upregulating the phosphorylation of STAT1 protein. Then, STAT1 promoted T-bet expression in CD4(+) T cells. In conclusion, Sch B modulates the differentiation of naive CD4(+) T cells into T(H)1 subset by STAT1/T-bet signaling, which may have the potential for the treatment of T cell-mediated-immune diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available